

(1999)) and the VHH portion can be readily cloned and expressed in yeast (Frenken, L. G. J., *et al. J. Biotechnol.* 78, 11-21 (2000)). Their levels of expression, solubility and stability are significantly higher than those of classical F(ab) or Fv fragments (Ghahroudi, M. A. *et al. FEBS Lett.* 414, 521-526 (1997)).

[0008] Mice in which the λ (lambda) light (L) chain locus and/or the λ and κ (kappa) L chain loci have been functionally silenced and antibodies produced by such mice are described in U.S. Patent Nos. 7,541,513 and 8,367,888. Recombinant production of heavy chain-only antibodies in mice and rats has been reported, for example, in WO2006008548; U.S. Application Publication No. 20100122358; Nguyen *et al.*, 2003, *Immunology*; 109(1), 93-101; Brüggemann *et al.*, *Crit. Rev. Immunol.*; 2006, 26(5):377-90; and Zou *et al.*, 2007, *J Exp Med*; 204(13): 3271–3283. The production of knockout rats via embryo microinjections of zinc-finger nucleases is described in Geurts *et al.*, 2009, *Science*, 325(5939):433. Soluble heavy chain-only antibodies and transgenic rodents comprising a heterologous heavy chain locus producing such antibodies are described in U. S. Patent Nos. 8,883,150 and 9,365,655. CAR-T structures comprising single-domain antibodies as binding (targeting) domain are described, for example, in Iri-Sofla *et al.*, 2011, *Experimental Cell Research* 317:2630-2641 and Jamnani *et al.*, 2014, *Biochim Biophys Acta*, 1840:378-386.

SUMMARY OF THE INVENTION

[0009] ~~Aspects~~Examples of the ~~invention~~disclosure refer to heavy chain antibodies, including, but not limited to, UniAbs™, with binding affinity to FOLR1. Further aspects-examples of the invention disclosure relate to methods of making such antibodies, compositions comprising such antibodies, and their use in the treatment of disorders that are characterized by the expression of FOLR1.

[00010] ~~Asepts of the invention~~Examples of the disclosure include antibodies that bind to FOLR1, comprising a first heavy chain variable region comprising: (a) a CDR1 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 1-5; and/or (b) a CDR2 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 6-17; and/or (c) a CDR3 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 18-22.

[00011] In some ~~embodiments~~examples, an antibody further comprises a second heavy chain variable region comprising: (a) a CDR1 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 1-5; and/or (b) a CDR2 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 6-17; and/or (c) a CDR3 having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 18-22.

[00012] In some ~~examples~~embodiments, said CDR1, CDR2, and CDR3 sequences are present in a human framework. In some ~~examples~~embodiments, an antibody further comprises a heavy chain constant region sequence in the absence of a CH1 sequence.

[00013] In some ~~examples~~embodiments, the first heavy chain variable region comprises: (a) a CDR1 sequence selected from the group consisting of SEQ ID NOs: 1-5; and/or (b) a CDR2 sequence selected from the

group consisting of SEQ ID NOs: 6-17; and/or (c) a CDR3 sequence selected from the group consisting of SEQ ID NOs: 18-22.

[00014] In some ~~example~~embodiments, the second heavy chain variable region comprises: (a) a CDR1 sequence selected from the group consisting of SEQ ID NOs: 1-5; and/or (b) a CDR2 sequence selected from the group consisting of SEQ ID NOs: 6-17; and/or (c) a CDR3 sequence selected from the group consisting of SEQ ID NOs: 18-22.

[00015] In some ~~example~~embodiments, the first heavy chain variable region comprises: (a) a CDR1 sequence selected from the group consisting of SEQ ID NOs: 1-5; and (b) a CDR2 sequence selected from the group consisting of SEQ ID NOs: 6-17; and (c) a CDR3 sequence selected from the group consisting of SEQ ID NOs: 18-22.

[00016] In some ~~example~~embodiments, the second heavy chain variable region comprises: (a) a CDR1 sequence selected from the group consisting of SEQ ID NOs: 1-5; and (b) a CDR2 sequence selected from the group consisting of SEQ ID NOs: 6-17; and (c) a CDR3 sequence selected from the group consisting of SEQ ID NOs: 18-22.

[00017] In some ~~example~~embodiments, an antibody comprises: (a) a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19; or (b) a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20.

[00018] In some ~~example~~embodiments, an antibody comprises a heavy chain variable region sequence having at least 95% sequence identity to any one of the sequences of SEQ ID NOs: 23-74. In some ~~example~~embodiments, an antibody comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 23-74. In some ~~example~~embodiments, the heavy chain variable region sequence is selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 49, SEQ ID NO: 61 and SEQ ID NO: 72.

[00019] ~~Aspects of the invention~~Examples of the disclosure include antibodies that bind to FOLR1, comprising a first heavy chain variable region comprising: (a) a CDR1 sequence of the formula: G F X1 F X2 S X3 X4 (SEQ ID NO: 75) where: X1 is N, T, I, or S; X2 is R or S; X3 is F or Y; and X4 is G, S, or T; and (b) a CDR2 sequence of the formula: I S S X1 S X2 X3 I (SEQ ID NO: 76) where: X1 is G or S; X2 is S or T; and X3 is Y, D, T, or S; and (c) a CDR3 sequence of the formula: A R D V T S G I A A A G X1 A F N I (SEQ ID NO: 77) where: X1 is A or S, in a monovalent or bivalent format.

[00020] ~~Examples of the disclosure~~Aspects of the invention include antibodies that bind to FOLR1, comprising a first heavy chain variable region comprising: (a) a CDR1 sequence of the formula: G F X1 F S S Y S (SEQ ID NO: 78) where: X1 is S or T; and (b) a CDR2 sequence of the formula: I X1 X2 S S X3 X4 I (SEQ ID NO: 79) where: X1 is S, T, or D; X2 is S, R, or G; X3 is D or S; and X4 is T or I; and (c) a CDR3 sequence of the formula: A X1 V G L X2 F D Y (SEQ ID NO: 80) where: X1 is S or T; and X2 is D or E, in a monovalent or bivalent format.

[00021] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a first heavy chain variable region comprising: (a) a CDR1 sequence of the formula: G F X1 F X2 S X3 X4 (SEQ ID NO:

75) where: X1 is N, T, I, or S; X2 is R or S; X3 is F or Y; and X4 is G, S, or T; and (b) a CDR2 sequence of the formula: I S S X1 S X2 X3 I (SEQ ID NO: 76) where: X1 is G or S; X2 is S or T; and X3 is Y, D, T, or S; and (c) a CDR3 sequence of the formula: A R D V T S G I A A A G X1 A F N I (SEQ ID NO: 77) where: X1 is A or S; and a second heavy chain variable region comprising: (a) a CDR1 sequence of the formula: G F X1 F S S Y S (SEQ ID NO: 78) where: X1 is S or T; and (b) a CDR2 sequence of the formula: I X1 X2 S S X3 X4 I (SEQ ID NO: 79) where: X1 is S, T, or D; X2 is S, R, or G; X3 is D or S; and X4 is T or I; and (c) a CDR3 sequence of the formula: A X1 V G L X2 F D Y (SEQ ID NO: 80) where: X1 is S or T; and X2 is D or E.

[00022] In some ~~embodiments~~examples, the first heavy chain variable region is located nearer to the N-terminus relative to the second heavy chain variable region. In some ~~embodiments~~examples, the first heavy chain variable region is located nearer to the C-terminus relative to the second heavy chain variable region.

[00023] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequences in a human VH framework, wherein the CDR sequences comprise a sequence having two or fewer substitutions in a CDR sequence selected from the group consisting of SEQ ID NOs: 1-22.

[00024] In some ~~examples~~embodiments, an antibody comprises a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequences in a human VH framework, wherein the CDR sequences are selected from the group consisting of SEQ ID NOs: 1-22.

[00025] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19 in a human VH framework.

[00026] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19 in a human VH framework, in a monovalent or bivalent configuration.

[00027] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20 in a human VH framework.

[00028] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20 in a human VH framework, in a monovalent or bivalent configuration.

[00029] Examples of the disclosure ~~Aspects of the invention~~ include antibodies that bind to FOLR1, comprising: a first heavy chain variable region comprising: a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework; and a second heavy chain

variable region comprising: a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework. In one aspect, it is referred to an antibody that binds to FOLR1, comprising a first heavy chain variable region comprising: (a) a CDR1 sequence having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 1-5; and (b) a CDR2 sequence having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 6-17; and (c) a CDR3 sequence having two or fewer substitutions in any of the amino acid sequences of SEQ ID NOs: 18-22. In another aspect, it is referred to an antibody that binds to FOLR1, comprising: (a) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19 in a human VH framework; or (b) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20 in a human VH framework. In yet another aspect, it is referred to an antibody that binds to FOLR1, comprising: (a) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19 in a human VH framework, in a monovalent or bivalent configuration; or (b) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20 in a human VH framework, in a monovalent or bivalent configuration. In another aspect, it is referred to a chimeric antigen receptor comprising an antibody as disclosed herein. In another aspect, it is referred to an antibody that binds to FOLR1, comprising: (a) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19 in a human VH framework, in a monovalent or bivalent configuration, or (b) a heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20 in a human VH framework, in a monovalent or bivalent configuration, or (c) a first heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework; and a second heavy chain variable region comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework, wherein the antibody is multi-specific and has binding affinity to CD3. In another aspect, it is referred to a bispecific antibody comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising: (A) a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework; or (B) a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework. In another aspect, it is referred to a bispecific antibody comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and a CDR3 sequence of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising: (A) a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework, in a monovalent or bivalent configuration; or (B) a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework, in a monovalent or bivalent configuration. In yet another aspect, it is referred to a bispecific antibody that binds to FOLR1 and CD3, comprising: (a) a first polypeptide comprising SEQ ID NO: 102; (b) a second polypeptide comprising SEQ ID NO: 103; and (c) a third polypeptide comprising SEQ ID NO: 104, 105, 106, 107, 108 or 109. In still another aspect, it is referred to an antibody as described herein for use in therapy.

[00030] In some ~~embodiments~~ examples, the first heavy chain variable region is located nearer to the N-terminus relative to the second heavy chain variable region. In some ~~embodiments~~ examples, the first heavy chain variable region is located nearer to the C-terminus relative to the second heavy chain variable region. In some ~~embodiments~~ examples, an antibody is monospecific. In some ~~embodiments~~ examples, an antibody is multi-specific. In some ~~embodiment~~ sexamples, an antibody is bispecific. In some ~~embodiments~~ examples, an antibody has binding affinity to a CD3 protein and an FOLR1 protein. In some ~~embodiments~~ examples, an antibody has binding affinity to two different epitopes on the same FOLR1 protein. In some ~~embodiments~~ examples, an antibody has binding affinity to an effector cell. In some ~~embodiments~~ examples, an antibody has binding affinity to a T-cell antigen. In some ~~embodiments~~ examples, an antibody has binding affinity to CD3. In some ~~embodiments~~ examples, an antibody is in a CAR-T format.

[00031] Examples of the disclosure ~~Aspects of the invention~~ include bispecific antibodies comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework.

[00032] Examples of the disclosure ~~Aspects of the invention~~ include bispecific antibodies comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework, in a monovalent or bivalent configuration.

[00033] Examples of the disclosure ~~Aspects of the invention~~ include bispecific antibodies comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework.

[00034] Examples of the disclosure ~~Aspects of the invention~~ include bispecific antibodies comprising:

- (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii)

a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, comprising a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework, in a monovalent or bivalent configuration.

[00035] Examples of the disclosure ~~Aspects of the invention~~ include multispecific antibodies comprising: (i) a heavy chain variable region having binding affinity to CD3, comprising a CDR1 sequence of SEQ ID NO: 83, a CDR2 sequence of SEQ ID NO: 84, and CDR3 sequence of SEQ ID NO: 85, in a human VH framework; (ii) a light chain variable region comprising a CDR1 sequence of SEQ ID NO: 86, a CDR2 sequence of SEQ ID NO: 87, and CDR3 sequences of SEQ ID NO: 88, in a human VL framework; and (iii) an antigen-binding domain of an anti-FOLR1 heavy chain antibody, wherein the antigen-binding domain comprises a first and a second antigen-binding region, in a bivalent configuration, wherein: the first antigen-binding region comprises a CDR1 sequence of SEQ ID NO: 2, a CDR2 sequence of SEQ ID NO: 6, and a CDR3 sequence of SEQ ID NO: 19, in a human VH framework; and the second antigen-binding region comprises a CDR1 sequence of SEQ ID NO: 4, a CDR2 sequence of SEQ ID NO: 16, and a CDR3 sequence of SEQ ID NO: 20, in a human VH framework.

[00036] In some -embodimentsexamples, the first antigen-binding region is located nearer to the N-terminus relative to the second antigen-binding region. In some -embodimentsexamples, the first antigen-binding region is located nearer to the C-terminus relative to the second antigen-binding region. In some -embodimentsexamples, the first and second antigen-binding regions of the antigen-binding domain of the anti-FOLR1 heavy chain antibody are connected by a polypeptide linker. In some embodimentsexamples, the polypeptide linker is a GS linker. In some -embodimentsexamples, the GS linker consists of the sequence of SEQ ID NO: 81 or SEQ ID NO: 82.

[00037] Examples of the disclosure ~~Aspects of the invention~~ include pharmaceutical compositions comprising an antibody as described herein.

[00038] Examples of the disclosure ~~Aspects of the invention~~ include methods for the treatment of a disorder characterized by expression of FOLR1, comprising administering to a subject with said disorder an antibody or a pharmaceutical composition as described herein.

[00039] Examples of the disclosure ~~Aspects of the invention~~ include use of an antibody as described herein, in the preparation of a medicament for the treatment of a disorder characterized by expression of FOLR1.

[00040] Examples of the disclosure ~~Aspects of the invention~~ include an antibody as described herein, for use in the treatment of a disorder characterized by expression of FOLR1.

[00041] In some -embodimentsexamples, the disorder is selected from the group consisting of: ovarian cancer, uterine cancers, lung cancer, renal cancer, colorectal cancer, breast cancer, and brain cancer.

| **[00042]** Examples of the disclosure ~~Aspects of the invention~~ include polynucleotides encoding an antibody as described herein, vectors comprising such polypeptides, and cells comprising such vectors.

[00043] Examples of the disclosure ~~Aspects of the invention~~ include methods of producing an antibody as described herein, comprising growing a cell as described herein under conditions permissive for expression of the antibody, and isolating the antibody from the cell.

[00044] Examples of the disclosure ~~Aspects of the invention~~ include methods of making an antibody as described herein, comprising immunizing a UniRat animal with an FOLR1 protein and identifying FOLR1-binding antibody sequences.

[00045] Examples of the disclosure ~~Aspects of the invention~~ include methods of treatment, comprising administering to an individual in need an effective dose of the antibody as described herein, or a pharmaceutical composition as described herein.

[00046] These and further aspects will be further explained in the rest of the disclosure, including the Examples.

BRIEF DESCRIPTION OF THE DRAWINGS

[00047] FIG. 1, panels A-E, provide a series of graphs showing results from anti-FOLR1 HCAb binding to FOLR1 positive cell lines.

[00048] FIG. 2, panels A-B, provide a series of graphs showing results from anti-FOLR1 HCAb binding to FOLR2 and IZUMO1R positive cell lines.

[00049] FIG. 3, panels A-C provide a series of graphs showing results from monovalent bispecific antibody-mediated killing of SKOV-3 human tumor cells through redirection of resting T cells. Panel A depicts levels of specific tumor cell lysis, panel B depicts IL-2 release, and panel C depicts IFN γ release. Panel D is an illustration of the monovalent bispecific antibody.

[00050] FIG. 4, panels A-C provide a series of graphs showing results from monovalent bispecific antibody-mediated killing of SKOV-3 human tumor cells through redirection of resting T cells. Panel A depicts levels of specific tumor cell lysis, panel B depicts IL-2 release, and panel C depicts IFN γ release. Panel D is an illustration of the monovalent bispecific antibody.

[00051] FIG. 5, panels A-C provide a series of graphs showing results from bivalent bispecific antibody-mediated killing of SKOV-3 human tumor cells through redirection of resting T cells. Panel A depicts levels of specific tumor cell lysis, panel B depicts IL-2 release, and panel C depicts IFN γ release. Panel D is an illustration of the bivalent bispecific antibody.

[00052] FIG. 6, panels A-C provide a series of graphs showing results from bivalent bispecific antibody-mediated killing of SKOV-3 human tumor cells through redirection of resting T cells. Panel A depicts levels of specific tumor cell lysis, panel B depicts IL-2 release, and panel C depicts IFN γ release. Panel D is an illustration of the bivalent bispecific antibody.

[00053] FIG. 7, panels A-C provide a series of graphs showing results from bivalent bispecific antibody-mediated killing of HT-29 human tumor cells through redirection of resting T cells. Panel A depicts